Joe Boscarino, PsyD @JBosc5

Neuropsychologist | FTD | substance use disorders | functional brain mapping | views = my own scholar.google.com/citations?user… Tampa, FL Joined February 2018

Tweets

346
Followers

271
Following

811
Likes

798

JAMA Psychiatry @JAMAPsych

7 months ago

Most viewed in the last 7 days from @JAMAPsych: Depressive symptoms were not consistently associated w/ amyloid pathology in individuals w/ normal cognition & were linked to a lower likelihood of amyloid pathology in those w/ mild cognitive impairment. ja.ma/3Eh8yzz

0 6 19 2K 4

Download Image

Talkin' Yanks @TalkinYanks

11 months ago

John Sterling's call of the Yankees becoming the 2024 AL Champions

57 1K 9K 371K 528

Download Video

Joaquín Migeot @joaquin_migeot

12 months ago

Impressive work on population attributable fractions of dementia risk factors in Latin America! The remarkable differences between countries highlight the need to address diversity to maximize the impact when addressing potentially modifiable risk factors for dementia.

Claudia Suemoto MD PhD MSc @clausuemoto

12 months ago

1 13 41 9K 8

0 25 62 7K 16

Download Image

Johannes Jungilligens @jungjoha

a year ago

European Medical Agency denies approval for Lecanemab - had to think about this article by ⁦@AlbertoEspay⁩ and colleagues: eneuro.org/content/11/7/E…

0 18 38 5K 12

Brain @Brain1878

a year ago

Using a novel PET tracer for imaging inflammation, Appleton et al. show that people with mild cognitive impairment with onset before the age of 65 years show brain inflammation that co-localizes with tau and correlates with cognitive impairment. tinyurl.com/2v6n2nrf

1 42 124 10K 36

Download Image

Alzheimer's Therapeutic Research Institute @ATRI_USC

a year ago

Researchers have announced the release of a massive dataset from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) and LEARN study – the first and largest clinical trial of pre-symptomatic Alzheimer's disease. atrinews.usc.edu/landmark-alzhe…

4 38 100 8K 36

Suzanne E Schindler @SuzanneESchind1

a year ago

Great work by Matt Brier finding a lower rate of amyloid pathology in older patients with multiple sclerosis. Also, interesting case of a cognitively unimpaired MS patient on immunosuppressive therapy with normal %p-tau217, very high amyloid PET burden (centiloid 109), and…

4 9 37 4K 7

Jed Barash @JedBarash

2 years ago

Really impressive 20 y study of CSF/imaging biomarker changes preceding Alzheimer’s @NEJM Divergence from normal group bf diagnosis: A beta: 18 years AB 42/AB 40: 14 phos tau 181: 11 Total tau: 10 Neurofil light chain: 9 Hippo vol: 8 Cog decline: 6 nejm.org/doi/full/10.10…

0 22 43 4K 15

Marianne Chapleau @M_Chapleau

2 years ago

Finally out in @TheLancetNeuro!!! Excited to share our multi-center study on demographic, clinical, biomarker, and neuropathological correlates in 1,092 patients with posterior cortical atrophy. The main findings are described below. thelancet.com/journals/laneu…

5 36 139 15K 15

Joel Geerling @geerling_lab

2 years ago

Textbook says measure the hippocampus, yet in many patients with Alzheimer’s disease, atrophy is predominantly 🧠 parietal & lateral temporal 🧠. New analysis of 2 EOAD cohorts: alz-journals.onlinelibrary.wiley.com/doi/pdfdirect/…

0 10 41 4K 6

Download Image

Danielle Beckman @DaniBeckman

2 years ago

Bad news in #Alzheimer research.. #solanezumab, a drug targeting monomeric amyloid-β species, did not slow cognitive decline in patients with preclinical Alzheimer's in a large cohort of patients. nejm.org/doi/full/10.10…

24 216 770 132K 97

Download Image

Simon Ducharme @sducharme66

2 years ago

New editorial out in Brain: Brain MRI research in neurodegenerative dementia: time to deliver on promises academic.oup.com/brain/article/…

8 28 86 18K 25

RikOssenkoppele @RikOssenkoppele

2 years ago

Below is an opportunity to provide feedback on the updated NIA-AA criteria, presented today by Cliff Jack at #AAIC23. NIA-AA Revised Clinical Guidelines for Alzheimer’s | AAIC aaic.alz.org/nia-aa.asp

0 22 45 5K 2

Michael T Duong MD PhD @DuongMDPhD

2 years ago

Know when #Alzheimers is #LATE #LATE is “Limbic-predominant Age-related TDP-43 Encephalopathy,” a memory disorder mimic of Alzheimers caused by a different protein, #TDP43. LATE has slower progression than AD but LATE+AD has faster progression than AD. onlinelibrary.wiley.com/doi/full/10.10…

2 10 23 3K 1

Download Image

Adit Friedberg @AditFriedberg

3 years ago

Why do some patients with #FTD unexpectedly become visually artistic? What can this teach us about neural mechanisms underlying human creativity? Check out our new @JAMANeuro paper bit.ly/FTDCreativity @brucemillerucsf @UCSFmac @GBHI_Fellows #creativity 🧠🎨🧵

5 45 110 22K 14

Michael Okun @MichaelOkun

3 years ago

Whether you believe in Braak hypothesis or not I like how Eidelberg's group is looking at functional imaging and thinking about how networks are affected as Parkinson's progresses and more symptoms emerge. Important to think networks! @foxmdphd nature.com/articles/s4158…

1 5 45 6K 6

Download Image

Michael Okun @MichaelOkun

3 years ago

Do you know all the sex differences in women vs. men with Dementia with Lewy Bodies? Women tend to be older, more visual hallucinations, meet criteria later. Nice article by @FixelInstitute Drs Chiu and Armstrong. prd-journal.com/article/S1353-…

0 8 37 6K 6

Download Image

Brain @Brain1878

3 years ago

In a randomized, double-blind, phase II trial, Koch et al. find that 24 weeks of repetitive transcranial magnetic stimulation of the precuneus slows down cognitive and functional decline in patients with Alzheimer’s disease. bit.ly/3SUOGnv

0 91 314 0 28

Download Image

Alberto J Espay @AlbertoEspay

3 years ago

A truly masterful analysis of the lecanemab data reported in @NEJM and #CTAD by @schrag_matthew: After 20+ years of clinical trials, amyloid-lowering therapy at best produces a barely detectable clinical effect.